Starting January 5, 2026, Novo Nordisk begins selling its FDA-approved Wegovy weight-loss pill in the US at lower self-pay ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

Novo Nordisk secured U.S. regulatory approval for its weight-loss pill, giving the Danish drugmaker a shot at reclaiming ...

Long-defined by high prices, shortages and weekly injections, weight loss drugs including Wegovy and Zepbound are expected to ...

The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

The weight loss drug market is bracing itself for a transformative year in 2026, with significant changes anticipated for GLP ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...

The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...

Denmark’s Novo Nordisk will offer its 1.5 and 4 ‍milligram Wegovy weightloss pills at US$149 (about RM685) per month ‌to self-paying patients in ...

Novo Nordisk has won the race to secure approval from the FDA for the first weight-loss drug to be administered orally ...

The U.S. Food and Drug Administration approved the oral medication on Monday for chronic weight management in adults with ...